Home » Archives for January 11, 2023
January 11, 2023
RECENT POSTS
ADVERTISEMENT
Case IH and New Holland Agriculture win four ASABE 2023 Innovation Awards
London, January 11, 2023 Case IH and New Holland, global agricultural brands of CNH Industrial, have won four 2023 ASABE AE50 awards from the American Society of Agricultural and Biological Engineers (ASABE). These prestigious awards honor the year’s 50 most innovative products and systems engineered for the food and agricultural
IIBA and HPRA Announce Strategic Partnership
New Certificate Program Incorporates Business Analysis to Enhance HR Function, Improving Business Outcomes TORONTO, Jan. 11, 2023 (GLOBE NEWSWIRE) — The International Institute of Business Analysis™ (IIBA®) and the Human Resources Professionals Association (HRPA) are proud to announce their strategic partnership. HRPA, serving the Ontario Province, have been advocating for
Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing
COLUMBUS, Ohio, Jan. 11, 2023 (GLOBE NEWSWIRE) — Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term care, and retail pharmacy providers, announced the acquisition of Tryten Technologies Inc., a designer and manufacturer of lightweight, easy to maneuver mobile cart solutions. Tryten is based in Langley, British
LambdaTest launches Test Analytics to enable better decision making
Test Analytics will be available for web browser automation, app automation, and HyperExecute users. The company has also released a slew of other product updates over the last quarter. San Francisco, Jan. 11, 2023 (GLOBE NEWSWIRE) — LambdaTest, the leading continuous quality testing cloud platform, has launched Test Analytics. Users
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition WALTHAM, Mass., Jan.